Mislav Mokos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mislav Mokos has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Mirna Situm
Department of Dermatology and Venereology, Sestre Milosrdnice University Hospital Center, 10000 Zagreb, Croatia
4 shared publications Davor Tomas
3 shared publicationsMirna Šitum
3 shared publications- Ana Brkić
Department of Dermatology and Venereology, Sestre Milosrdnice University Hospital Center, 10000 Zagreb, Croatia
2 shared publications - Ivana Prkačin
Department of Dermatology and Venereology, Sestre Milosrdnice University Hospital Center, 10000 Zagreb, Croatia
2 shared publications - Klara Gaćina
Department of Dermatology and Venereology, University Hospital Centre Sestre Milosrdnice, 10000 Zagreb, Croatia
2 shared publications
Latest Publications
- Open Access
- 3 March 2026
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 16 (3) , 147
From Immunobiology to Clinical Application: Tumor-Infiltrating Lymphocytes in Melanoma
Background: Tumor-infiltrating lymphocytes (TILs) play a key role in the immune response against melanoma. They act as both markers of an active tumor environment and as treatments in adoptive cell therapy. This narrative review covers what is currently known about TIL biology, their prognostic and predictive value, and the use of TIL-based adoptive cell therapy (TIL-ACT) in advanced melanoma. Methods: We searched PubMed/MEDLINE, Web of Science and clinicaltrials.gov through January 2026 using terms related to melanoma, TILs, adoptive cell therapy, immune checkpoint inhibitors, neoantigens, T-cell receptor clonality, and spatial transcriptomics. We included original research, major clinical trials, translational studies and key reviews. Results: Melanoma often has many neoantigens, which leads to a high number of tumor-resident TILs. These TILs, their arrangement, and their interactions with myeloid cells influence how well they fight tumors. Features of TILs seen under the microscope and through other tests can help predict patient outcomes, even before treatment. Studies show that TIL-ACT leads to objective responses in about 30–50% of patients whose melanoma did not respond to immune checkpoint inhibitors. Some patients achieve lasting complete remissions, though the treatment can cause significant, mostly short-term side effects from lymphodepletion and interleukin-2. New research points to factors related to the patient, tumor, and TIL product that affect treatment success, supporting the use of biomarkers and combination strategies. Conclusions: TIL-based adoptive cell therapy is now a promising, personalized treatment for advanced melanoma after anti-PD-1 therapy has failed. Future studies should focus on identifying reliable biomarkers, improving TIL products, combining therapies to change the tumor environment, and making manufacturing more efficient to ensure more patients can safely access TIL therapy.
- 3 March 2026
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 16 (3) , 147
Open AccessFrom Immunobiology to Clinical Application: Tumor-Infiltrating Lymphocytes in Melanoma
Background: Tumor-infiltrating lymphocytes (TILs) play a key role in the immune response against melanoma. They act as both markers of an active tumor environment and as treatments in adoptive cell therapy. This narrative review covers what is currently known about TIL biology, their prognostic and predictive value, and the use of TIL-based adoptive cell therapy (TIL-ACT) in advanced melanoma. Methods: We searched PubMed/MEDLINE, Web of Science and clinicaltrials.gov through January 2026 using terms related to melanoma, TILs, adoptive cell therapy, immune checkpoint inhibitors, neoantigens, T-cell receptor clonality, and spatial transcriptomics. We included original research, major clinical trials, translational studies and key reviews. Results: Melanoma often has many neoantigens, which leads to a high number of tumor-resident TILs. These TILs, their arrangement, and their interactions with myeloid cells influence how well they fight tumors. Features of TILs seen under the microscope and through other tests can help predict patient outcomes, even before treatment. Studies show that TIL-ACT leads to objective responses in about 30–50% of patients whose melanoma did not respond to immune checkpoint inhibitors. Some patients achieve lasting complete remissions, though the treatment can cause significant, mostly short-term side effects from lymphodepletion and interleukin-2. New research points to factors related to the patient, tumor, and TIL product that affect treatment success, supporting the use of biomarkers and combination strategies. Conclusions: TIL-based adoptive cell therapy is now a promising, personalized treatment for advanced melanoma after anti-PD-1 therapy has failed. Future studies should focus on identifying reliable biomarkers, improving TIL products, combining therapies to change the tumor environment, and making manufacturing more efficient to ensure more patients can safely access TIL therapy.
- 1 December 2025
- Vol. 33 (4) , 168-173
Atypical Presentation of Sweet's Syndrome: A Case Report and Review of the Literature.
Sweet's syndrome (acute febrile neutrophilic dermatosis) is an inflammatory condition characterized by the abrupt onset of erythematous, oedematous plaques or nodules and a dense neutrophilic dermal infiltrate. Although usually associated with fever and tender lesions on the face and upper extremities, its clinical spectrum is broad, and atypical presentations may pose diagnostic challenges. We report the case of a 50-year-old female patient who presented with an acute eruption of widespread, annular, erythematous, and oedematous plaques predominantly involving the trunk and extremities, accompanied by severe pruritus. The patient denied fever or other systemic symptoms. Laboratory investigations demonstrated marked leukocytosis with neutrophilia and elevated inflammatory markers. An extensive infectious, immunological, and malignancy workup was unremarkable. Histopathological examination revealed a dense neutrophilic dermal infiltrate with leukocytoclasia in the absence of true vasculitis, consistent with Sweet's syndrome. Direct immunofluorescence was negative. The patient reported a history of similar episodic eruptions over two decades, often temporally associated with respiratory infections. Systemic glucocorticoid therapy led to rapid clinical improvement and normalization of inflammatory parameters, with complete resolution at follow-up. This case highlights the clinical heterogeneity of Sweet's syndrome, demonstrating that prominent pruritus, truncal predominance, and afebrile presentation may occur. Recognition of atypical manifestations is essential to avoid misdiagnosis, particularly with urticarial or allergic disorders. Thorough evaluation for associated systemic disease and careful documentation of recurrent patterns remain crucial. Early histopathological confirmation and prompt initiation of appropriate therapy enable rapid disease control and favourable outcomes.
- 1 December 2025
- Vol. 33 (4) , 168-173
Atypical Presentation of Sweet's Syndrome: A Case Report and Review of the Literature.
Sweet's syndrome (acute febrile neutrophilic dermatosis) is an inflammatory condition characterized by the abrupt onset of erythematous, oedematous plaques or nodules and a dense neutrophilic dermal infiltrate. Although usually associated with fever and tender lesions on the face and upper extremities, its clinical spectrum is broad, and atypical presentations may pose diagnostic challenges. We report the case of a 50-year-old female patient who presented with an acute eruption of widespread, annular, erythematous, and oedematous plaques predominantly involving the trunk and extremities, accompanied by severe pruritus. The patient denied fever or other systemic symptoms. Laboratory investigations demonstrated marked leukocytosis with neutrophilia and elevated inflammatory markers. An extensive infectious, immunological, and malignancy workup was unremarkable. Histopathological examination revealed a dense neutrophilic dermal infiltrate with leukocytoclasia in the absence of true vasculitis, consistent with Sweet's syndrome. Direct immunofluorescence was negative. The patient reported a history of similar episodic eruptions over two decades, often temporally associated with respiratory infections. Systemic glucocorticoid therapy led to rapid clinical improvement and normalization of inflammatory parameters, with complete resolution at follow-up. This case highlights the clinical heterogeneity of Sweet's syndrome, demonstrating that prominent pruritus, truncal predominance, and afebrile presentation may occur. Recognition of atypical manifestations is essential to avoid misdiagnosis, particularly with urticarial or allergic disorders. Thorough evaluation for associated systemic disease and careful documentation of recurrent patterns remain crucial. Early histopathological confirmation and prompt initiation of appropriate therapy enable rapid disease control and favourable outcomes.
- Open Access
- 28 November 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (12) , 2921
Hypochlorous Acid: Clinical Insights and Experience in Dermatology, Surgery, Dentistry, Ophthalmology, Rhinology, and Other Specialties
Background: Hypochlorous acid (HOCl) is an integral component of the human innate immune system. It possesses antimicrobial properties and is available in solution, dermal spray, and scar gel forms. Objectives/Methods: This review presents data from studies on the clinical use of HOCl in various specialties, including dermatology, surgery, dentistry, ophthalmology, and rhinology. Results: Due to its anti-inflammatory/antimicrobial/immunomodulatory and healing properties, HOCl is advantageous in treating various skin disorders: ulcus cruris (and wound care), diabetic ulcers, atopic dermatitis, seborrheic dermatitis, pruritus, acne vulgaris, etc. Also, the application of a HOCl spray/gel after surgical procedures may prevent infection, reduce inflammation, and accelerate healing. HOCl is also effective and safe for the prevention and treatment of hypertrophic and keloid scars. Growing evidence shows a broader role for HOCl in limiting cancer cell survival and slowing tumor growth. It is also important in treating various viral infections like SARS-CoV-2 (coronavirus), influenza, and herpes, thereby helping to prevent the spread of aerosols. In addition, since HOCl is an endogenous compound naturally present in mammals with a high safety profile, it may be an effective bacterial disinfectant in dental waterlines. In ophthalmology, adjuvant treatment with HOCl ophthalmic spray can reduce the duration of antibiotic/corticosteroid use, even in severe blepharitis. To fully harness the protective/therapeutic properties of HOCl, future advancements will rely on the development of new chemical compounds and sophisticated pharmaceutical formulations. Conclusions: The majority of clinical studies have confirmed that HOC1 is useful in therapy, although the results are not entirely consistent. Further research is essential to optimize HOCl dosing and to develop controlled-release systems aimed at maximizing its anti-inflammatory and photoprotective effects while minimizing tissue irritation and damage.
- 28 November 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (12) , 2921
Open AccessHypochlorous Acid: Clinical Insights and Experience in Dermatology, Surgery, Dentistry, Ophthalmology, Rhinology, and Other Specialties
Background: Hypochlorous acid (HOCl) is an integral component of the human innate immune system. It possesses antimicrobial properties and is available in solution, dermal spray, and scar gel forms. Objectives/Methods: This review presents data from studies on the clinical use of HOCl in various specialties, including dermatology, surgery, dentistry, ophthalmology, and rhinology. Results: Due to its anti-inflammatory/antimicrobial/immunomodulatory and healing properties, HOCl is advantageous in treating various skin disorders: ulcus cruris (and wound care), diabetic ulcers, atopic dermatitis, seborrheic dermatitis, pruritus, acne vulgaris, etc. Also, the application of a HOCl spray/gel after surgical procedures may prevent infection, reduce inflammation, and accelerate healing. HOCl is also effective and safe for the prevention and treatment of hypertrophic and keloid scars. Growing evidence shows a broader role for HOCl in limiting cancer cell survival and slowing tumor growth. It is also important in treating various viral infections like SARS-CoV-2 (coronavirus), influenza, and herpes, thereby helping to prevent the spread of aerosols. In addition, since HOCl is an endogenous compound naturally present in mammals with a high safety profile, it may be an effective bacterial disinfectant in dental waterlines. In ophthalmology, adjuvant treatment with HOCl ophthalmic spray can reduce the duration of antibiotic/corticosteroid use, even in severe blepharitis. To fully harness the protective/therapeutic properties of HOCl, future advancements will rely on the development of new chemical compounds and sophisticated pharmaceutical formulations. Conclusions: The majority of clinical studies have confirmed that HOC1 is useful in therapy, although the results are not entirely consistent. Further research is essential to optimize HOCl dosing and to develop controlled-release systems aimed at maximizing its anti-inflammatory and photoprotective effects while minimizing tissue irritation and damage.
- 1 September 2025
- Vol. 33 (3) , 143-144
Long-Term Remission in Stage IIIb Melanoma After Surgical Resection Alone: An Uncommon Clinical Scenario.
Dear Editor, Melanoma is one of the most aggressive skin cancers, with rising global incidence (1). Prognosis is closely linked to the stage at diagnosis, with stage III, particularly cases involving lymph node metastases, carrying a high risk of relapse and mortality (2). Standard treatment includes wide local excision, sentinel lymph node biopsy, and systemic adjuvant therapy in metastatic cases (3). Despite these measures, five-year survival for stage IIIB melanoma remains significantly lower than for earlier stages (2). Herein, we report a rare case of stage IIIB melanoma with over ten years of relapse-free survival following surgical management alone, challenging typical prognostic expectations. A 70-year-old male was referred to our department in June 2011 after the excision of two melanomas: a superficial spreading melanoma (SSM) on the right forearm (Clark III, Breslow 1.1 mm) and a nodular melanoma on the upper back (Clark IV, Breslow 2.4 mm). On both locations wider surgical excision has subsequently been performed, according to contemporary guidelines for melanoma management, and sentinel lymph node biopsy in August 2011 revealed no metastases. The patient underwent routine surveillance with clinical exams, dermoscopy, and lymph node ultrasound. In October 2014, an enlarged left cervical lymph node was identified. Fine-needle aspiration was inconclusive, but surgical excision confirmed metastatic melanoma (Figure 1). A PET/CT scan in November 2014 revealed a hypermetabolic lymph node in region I of the left neck. A subsequent radical neck dissection in December 2014 removed eleven lymph nodes, none of which showed metastasis. The disease was classified as stage IIIB melanoma. The patient declined systemic therapy with vemurafenib. He later underwent surgical treatment for two new primary SSMs: one on the posterior neck in October 2016 (Clark II, Breslow 0.45 mm) and another on the left lumbar region in February 2019 (Clark II, Breslow 0.48 mm). Both were excised with clear margins and scar re-excisions. As of January 2025, the patient remains in remission with no signs of recurrence or metastasis, under continued follow-up with dermoscopy, lymph node ultrasound, and S100B monitoring, which is more than ten years after the diagnosis of metastatic melanoma. Stage IIIB melanoma is typically associated with a guarded prognosis, and systemic therapy is often recommended to mitigate the risk of relapse (2,3). The five-year melanoma-specific survival rate for this stage varies but is generally estimated at approximately 75% to 83% (2). Standard therapeutic protocols include BRAF inhibitors, MEK inhibitors, and immune checkpoint inhibitors, which have demonstrated significant efficacy in reducing recurrence and improving overall survival (3). However, not all patients are candidates for or opt to receive these treatments. The present case is exceptional due to the prolonged duration of relapse-free survival despite the absence of systemic therapy. The favorable outcome may be attributed to several factors, including early detection, complete surgical removal of all identified lesions, low tumor burden at the time of metastatic lymph node involvement, and the absence of ulceration or high mitotic activity. Furthermore, meticulous follow-up and adherence to surveillance protocols likely contributed to the timely identification and management of additional primary melanomas (4). Although adjuvant systemic therapy remains the recommended standard of care for stage IIIB melanoma, this exceptional case illustrates that, in rare circumstances, long-term remission may be achieved with surgery alone. Rather than challenging standard practice, this case highlights the need for research into prognostic and predictive biomarkers that could refine risk stratification within this heterogeneous disease stage.
- 1 September 2025
- Vol. 33 (3) , 143-144
Long-Term Remission in Stage IIIb Melanoma After Surgical Resection Alone: An Uncommon Clinical Scenario.
Dear Editor, Melanoma is one of the most aggressive skin cancers, with rising global incidence (1). Prognosis is closely linked to the stage at diagnosis, with stage III, particularly cases involving lymph node metastases, carrying a high risk of relapse and mortality (2). Standard treatment includes wide local excision, sentinel lymph node biopsy, and systemic adjuvant therapy in metastatic cases (3). Despite these measures, five-year survival for stage IIIB melanoma remains significantly lower than for earlier stages (2). Herein, we report a rare case of stage IIIB melanoma with over ten years of relapse-free survival following surgical management alone, challenging typical prognostic expectations. A 70-year-old male was referred to our department in June 2011 after the excision of two melanomas: a superficial spreading melanoma (SSM) on the right forearm (Clark III, Breslow 1.1 mm) and a nodular melanoma on the upper back (Clark IV, Breslow 2.4 mm). On both locations wider surgical excision has subsequently been performed, according to contemporary guidelines for melanoma management, and sentinel lymph node biopsy in August 2011 revealed no metastases. The patient underwent routine surveillance with clinical exams, dermoscopy, and lymph node ultrasound. In October 2014, an enlarged left cervical lymph node was identified. Fine-needle aspiration was inconclusive, but surgical excision confirmed metastatic melanoma (Figure 1). A PET/CT scan in November 2014 revealed a hypermetabolic lymph node in region I of the left neck. A subsequent radical neck dissection in December 2014 removed eleven lymph nodes, none of which showed metastasis. The disease was classified as stage IIIB melanoma. The patient declined systemic therapy with vemurafenib. He later underwent surgical treatment for two new primary SSMs: one on the posterior neck in October 2016 (Clark II, Breslow 0.45 mm) and another on the left lumbar region in February 2019 (Clark II, Breslow 0.48 mm). Both were excised with clear margins and scar re-excisions. As of January 2025, the patient remains in remission with no signs of recurrence or metastasis, under continued follow-up with dermoscopy, lymph node ultrasound, and S100B monitoring, which is more than ten years after the diagnosis of metastatic melanoma. Stage IIIB melanoma is typically associated with a guarded prognosis, and systemic therapy is often recommended to mitigate the risk of relapse (2,3). The five-year melanoma-specific survival rate for this stage varies but is generally estimated at approximately 75% to 83% (2). Standard therapeutic protocols include BRAF inhibitors, MEK inhibitors, and immune checkpoint inhibitors, which have demonstrated significant efficacy in reducing recurrence and improving overall survival (3). However, not all patients are candidates for or opt to receive these treatments. The present case is exceptional due to the prolonged duration of relapse-free survival despite the absence of systemic therapy. The favorable outcome may be attributed to several factors, including early detection, complete surgical removal of all identified lesions, low tumor burden at the time of metastatic lymph node involvement, and the absence of ulceration or high mitotic activity. Furthermore, meticulous follow-up and adherence to surveillance protocols likely contributed to the timely identification and management of additional primary melanomas (4). Although adjuvant systemic therapy remains the recommended standard of care for stage IIIB melanoma, this exceptional case illustrates that, in rare circumstances, long-term remission may be achieved with surgery alone. Rather than challenging standard practice, this case highlights the need for research into prognostic and predictive biomarkers that could refine risk stratification within this heterogeneous disease stage.
- Open Access
- 15 August 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (8) , 1988
Therapeutic Opportunities in Melanoma Through PRAME Expression
Background: Melanoma is one of the most aggressive types of skin cancer. Its diagnosis appears to be challenging due to morphological similarities to benign melanocytic lesions. Even though histopathological evaluation is the diagnostic gold standard, immunohistochemistry (IHC) proves to be useful in challenging cases. Preferentially Expressed Antigen in Melanoma (PRAME) has emerged as a promising diagnostic, prognostic, and therapeutic marker in melanoma. Methods: This review critically examines the role of PRAME across clinical domains. It presents an evaluation of PRAME’s diagnostic utility in differentiating melanomas from benign nevi, its prognostic significance across melanoma subtypes, and therapeutic applications in emerging immunotherapy strategies. An extensive analysis of the current literature was conducted, with a focus on PRAME expression patterns in melanocytic lesions and various malignancies, along with its integration into IHC protocols and investigational therapies. Results: PRAME demonstrates high specificity and sensitivity in distinguishing melanoma from benign melanocytic proliferations, particularly in challenging subtypes such as acral, mucosal, and spitzoid lesions. Its overexpression correlates with poor prognosis in numerous malignancies. Therapeutically, PRAME’s HLA class I presentation enables T-cell-based targeting. Early-phase trials show promising results using PRAME-directed TCR therapies and bispecific ImmTAC agents. However, immune evasion mechanisms (i.e., heterogeneous antigen expression, immune suppression in the tumor microenvironment, and HLA downregulation) pose significant challenges to therapy. Conclusions: PRAME is a valuable biomarker for melanoma diagnosis and a promising target for immunotherapy. Its selective expression in malignancies supports its clinical utility in diagnostic precision, prognostic assessment, and precision oncology. Ongoing research aimed at overcoming immunological barriers will be essential for optimizing PRAME-directed therapies and establishing their place in the personalized management of melanoma.
- 15 August 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (8) , 1988
Open AccessTherapeutic Opportunities in Melanoma Through PRAME Expression
Background: Melanoma is one of the most aggressive types of skin cancer. Its diagnosis appears to be challenging due to morphological similarities to benign melanocytic lesions. Even though histopathological evaluation is the diagnostic gold standard, immunohistochemistry (IHC) proves to be useful in challenging cases. Preferentially Expressed Antigen in Melanoma (PRAME) has emerged as a promising diagnostic, prognostic, and therapeutic marker in melanoma. Methods: This review critically examines the role of PRAME across clinical domains. It presents an evaluation of PRAME’s diagnostic utility in differentiating melanomas from benign nevi, its prognostic significance across melanoma subtypes, and therapeutic applications in emerging immunotherapy strategies. An extensive analysis of the current literature was conducted, with a focus on PRAME expression patterns in melanocytic lesions and various malignancies, along with its integration into IHC protocols and investigational therapies. Results: PRAME demonstrates high specificity and sensitivity in distinguishing melanoma from benign melanocytic proliferations, particularly in challenging subtypes such as acral, mucosal, and spitzoid lesions. Its overexpression correlates with poor prognosis in numerous malignancies. Therapeutically, PRAME’s HLA class I presentation enables T-cell-based targeting. Early-phase trials show promising results using PRAME-directed TCR therapies and bispecific ImmTAC agents. However, immune evasion mechanisms (i.e., heterogeneous antigen expression, immune suppression in the tumor microenvironment, and HLA downregulation) pose significant challenges to therapy. Conclusions: PRAME is a valuable biomarker for melanoma diagnosis and a promising target for immunotherapy. Its selective expression in malignancies supports its clinical utility in diagnostic precision, prognostic assessment, and precision oncology. Ongoing research aimed at overcoming immunological barriers will be essential for optimizing PRAME-directed therapies and establishing their place in the personalized management of melanoma.
- Open Access
- 4 August 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (8) , 1894
Adjuvant Immunotherapy in Stage IIB/IIC Melanoma: Current Evidence and Future Directions
Background: Patients with resected stage IIB and IIC melanoma are at high risk of recurrence and distant metastasis, despite surgical treatment. The recent emergence of immune checkpoint inhibitors (ICIs) has led to their evaluation in the adjuvant setting for early-stage disease. This review aims to synthesize current evidence regarding adjuvant immunotherapy for stage IIB/IIC melanoma, explore emerging strategies, and highlight key challenges and future directions. Methods: We conducted a comprehensive literature review of randomized clinical trials, observational studies, and relevant mechanistic and biomarker research on adjuvant therapy in stage IIB/IIC melanoma. Particular focus was placed on pivotal trials evaluating PD-1 inhibitors (KEYNOTE-716 and CheckMate 76K), novel vaccine and targeted therapy trials, mechanisms of resistance, immune-related toxicity, and biomarker development. Results: KEYNOTE-716 and CheckMate 76K demonstrated significant improvements in recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) with pembrolizumab and nivolumab, respectively, compared to placebo. However, no definitive overall survival benefit has yet been shown. Adjuvant immunotherapy is linked to immune-related adverse events, including permanent endocrinopathies. Emerging personalized approaches, such as circulating tumor DNA monitoring and gene expression profiling, may enhance patient selection, but remain investigational. Conclusions: Adjuvant PD-1 blockade offers clear RFS benefits in high-risk stage II melanoma, but optimal patient selection remains challenging, due to uncertain overall survival benefit and toxicity concerns. Future trials should integrate biomarker-driven approaches to refine therapeutic decisions and minimize overtreatment.
- 4 August 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (8) , 1894
Open AccessAdjuvant Immunotherapy in Stage IIB/IIC Melanoma: Current Evidence and Future Directions
Background: Patients with resected stage IIB and IIC melanoma are at high risk of recurrence and distant metastasis, despite surgical treatment. The recent emergence of immune checkpoint inhibitors (ICIs) has led to their evaluation in the adjuvant setting for early-stage disease. This review aims to synthesize current evidence regarding adjuvant immunotherapy for stage IIB/IIC melanoma, explore emerging strategies, and highlight key challenges and future directions. Methods: We conducted a comprehensive literature review of randomized clinical trials, observational studies, and relevant mechanistic and biomarker research on adjuvant therapy in stage IIB/IIC melanoma. Particular focus was placed on pivotal trials evaluating PD-1 inhibitors (KEYNOTE-716 and CheckMate 76K), novel vaccine and targeted therapy trials, mechanisms of resistance, immune-related toxicity, and biomarker development. Results: KEYNOTE-716 and CheckMate 76K demonstrated significant improvements in recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) with pembrolizumab and nivolumab, respectively, compared to placebo. However, no definitive overall survival benefit has yet been shown. Adjuvant immunotherapy is linked to immune-related adverse events, including permanent endocrinopathies. Emerging personalized approaches, such as circulating tumor DNA monitoring and gene expression profiling, may enhance patient selection, but remain investigational. Conclusions: Adjuvant PD-1 blockade offers clear RFS benefits in high-risk stage II melanoma, but optimal patient selection remains challenging, due to uncertain overall survival benefit and toxicity concerns. Future trials should integrate biomarker-driven approaches to refine therapeutic decisions and minimize overtreatment.
- 1 May 2025
- Vol. 33 (1) , 40-41
Incidental Nodal Nevus in the Sentinel Lymph Node of a Melanoma Patient.
Dear Editor, Sentinel lymph node biopsy (SLNB) is crucial for melanoma staging, but the presence of nodal nevi (NN) can complicate diagnosis by mimicking metastatic melanoma. Misclassification occurs in over 10% of cases, potentially leading to overtreatment [1]. We present a case of a 53-year-old woman with superficial spreading melanoma (SSM), where SLNB revealed a capsular NN without metastasis. A 53-year-old female patient was referred to our department with an atypical nevus on her right calf. Following its excision, histological analysis confirmed the diagnosis of SSM with a Breslow thickness of 1.80 mm, classified as stage pT2a. The tumor exhibited three mitoses per mm², no evidence of lymphovascular invasion, and a mild chronic inflammatory infiltrate at its base. According to current recommendations, a re-excision of the postoperative scar with SLNB was performed. Histological analysis found no metastases in the scar tissue or the sentinel lymph node (SLN). However, a small, capsular NN was identified within the SLN (Figure 1). Benign melanocytic nevus cell aggregates, commonly referred to as NN, are typically found within the capsule or trabeculae of lymph nodes, as seen in our patient [2]. The origin of NN cells is debated, with two main theories: embryological migration from the neuroectoderm or lymphatic migration from cutaneous nevi. Recent study findings, particularly the intracapsular location of nevus cells and their higher prevalence in melanoma patients than in breast cancer patients, support the hypothesis that these cells migrate via lymphatic routes rather than being remnants of embryonic development [3]. When NN appear in SLNs, which is estimated to be the case in 1% to 11% of SLNBs, they may present significant diagnostic challenges in melanoma patients [4]. Typically, NN are small, triangular, and lack cytonuclear atypia and mitotic activity, distinguishing them from metastatic melanoma, which is usually found in the parenchyma. However, when nevi extend into the parenchyma or paratrabecular areas, they can mimic metastases, making the differential diagnosis challenging, especially for small melanoma metastases with nevoid morphology [1]. A specialized review of SLNB samples initially classified as melanoma-positive revealed that over 10% were misdiagnosed cases of NN [1]. This diagnostic ambiguity between NN and true SLN metastases carries serious implications, as misclassification can lead to either overtreatment or undertreatment of the patient. On the other hand, the updated EORTC protocol demonstrated a high incidence of NN in SLNBs and identified a strong association between NN and nevus-associated melanoma [4]. Furthermore, Kretschmer et al. demonstrated that SLN-negative melanoma patients with NN exhibited a slightly lower survival rate, while SLN-positive melanoma patients who had both NN and melanoma metastases showed a marginally better prognosis compared to those with metastases alone. However, these differences in survival were not statistically significant [2]. This case highlights the diagnostic challenge of NN in SLNBs for melanoma. While NN can mimic metastases, accurate histopathological evaluation is crucial to prevent overtreatment. Our patient's case, along with existing research, supports the need for careful differentiation between NN and true metastases to ensure appropriate clinical management.
- 1 May 2025
- Vol. 33 (1) , 40-41
Incidental Nodal Nevus in the Sentinel Lymph Node of a Melanoma Patient.
Dear Editor, Sentinel lymph node biopsy (SLNB) is crucial for melanoma staging, but the presence of nodal nevi (NN) can complicate diagnosis by mimicking metastatic melanoma. Misclassification occurs in over 10% of cases, potentially leading to overtreatment [1]. We present a case of a 53-year-old woman with superficial spreading melanoma (SSM), where SLNB revealed a capsular NN without metastasis. A 53-year-old female patient was referred to our department with an atypical nevus on her right calf. Following its excision, histological analysis confirmed the diagnosis of SSM with a Breslow thickness of 1.80 mm, classified as stage pT2a. The tumor exhibited three mitoses per mm², no evidence of lymphovascular invasion, and a mild chronic inflammatory infiltrate at its base. According to current recommendations, a re-excision of the postoperative scar with SLNB was performed. Histological analysis found no metastases in the scar tissue or the sentinel lymph node (SLN). However, a small, capsular NN was identified within the SLN (Figure 1). Benign melanocytic nevus cell aggregates, commonly referred to as NN, are typically found within the capsule or trabeculae of lymph nodes, as seen in our patient [2]. The origin of NN cells is debated, with two main theories: embryological migration from the neuroectoderm or lymphatic migration from cutaneous nevi. Recent study findings, particularly the intracapsular location of nevus cells and their higher prevalence in melanoma patients than in breast cancer patients, support the hypothesis that these cells migrate via lymphatic routes rather than being remnants of embryonic development [3]. When NN appear in SLNs, which is estimated to be the case in 1% to 11% of SLNBs, they may present significant diagnostic challenges in melanoma patients [4]. Typically, NN are small, triangular, and lack cytonuclear atypia and mitotic activity, distinguishing them from metastatic melanoma, which is usually found in the parenchyma. However, when nevi extend into the parenchyma or paratrabecular areas, they can mimic metastases, making the differential diagnosis challenging, especially for small melanoma metastases with nevoid morphology [1]. A specialized review of SLNB samples initially classified as melanoma-positive revealed that over 10% were misdiagnosed cases of NN [1]. This diagnostic ambiguity between NN and true SLN metastases carries serious implications, as misclassification can lead to either overtreatment or undertreatment of the patient. On the other hand, the updated EORTC protocol demonstrated a high incidence of NN in SLNBs and identified a strong association between NN and nevus-associated melanoma [4]. Furthermore, Kretschmer et al. demonstrated that SLN-negative melanoma patients with NN exhibited a slightly lower survival rate, while SLN-positive melanoma patients who had both NN and melanoma metastases showed a marginally better prognosis compared to those with metastases alone. However, these differences in survival were not statistically significant [2]. This case highlights the diagnostic challenge of NN in SLNBs for melanoma. While NN can mimic metastases, accurate histopathological evaluation is crucial to prevent overtreatment. Our patient's case, along with existing research, supports the need for careful differentiation between NN and true metastases to ensure appropriate clinical management.
- Open Access
- 30 April 2025
- Published by Mattioli1885 in Dermatology Practical & Conceptual
- Vol. 15 (2) , 4912
Significant Nevi Regression Associated with Multiple Non-Metastatic Cutaneous Melanomas: A Case Report
- 30 April 2025
- Published by Mattioli1885 in Dermatology Practical & Conceptual
- Vol. 15 (2) , 4912
Open AccessSignificant Nevi Regression Associated with Multiple Non-Metastatic Cutaneous Melanomas: A Case Report
- Open Access
- 12 June 2023
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 48 (1) , 505-514
Histopathological Features of Time-Zero Kidney Biopsy Are Predictive Factors for Posttransplant Anemia
Introduction: Posttransplant anemia (PTA) is a common complication of kidney transplantation, associated with reduced graft survival and higher mortality. We aimed to determine the association of PTA with histopathological characteristics of time-zero allograft biopsy and donor clinical characteristics. Methods: We conducted a retrospective, observational cohort study that included 587 patients who underwent kidney transplantation in our center. Hemoglobin levels were assessed at 6 and 12 months after transplantation, and anemia was defined according to World Health Organization criteria. The kidney allograft time-zero biopsy has been done in all investigated cases. The evaluated histopathological parameters of the kidney allografts included glomerulosclerosis, arteriolar hyalinosis (AH), vascular fibrous intimal thickening (CV), interstitial fibrosis, tubular atrophy, and interstitial fibrosis and tubular atrophy. The Banff Classification of Allograft Pathology criteria were followed to assess the allograft histopathological changes. Results: The prevalence of anemia was 31.3% at 6 months after transplantation and 23.5% at 12 months. There was an association between 20-50% glomerulosclerosis and PTA in both time points, independently from estimated glomerular filtration rate. AH and interstitial fibrosis were identified as independent risk factors for anemia 6 months after transplantation. Conclusion: Histopathological features of time-zero kidney biopsy may be predictors of PTA. Among them, our study recognized 20–50% degree of glomerulosclerosis, AH, and CV as the most significant risk factors for PTA.
- 12 June 2023
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 48 (1) , 505-514
Open AccessHistopathological Features of Time-Zero Kidney Biopsy Are Predictive Factors for Posttransplant Anemia
Introduction: Posttransplant anemia (PTA) is a common complication of kidney transplantation, associated with reduced graft survival and higher mortality. We aimed to determine the association of PTA with histopathological characteristics of time-zero allograft biopsy and donor clinical characteristics. Methods: We conducted a retrospective, observational cohort study that included 587 patients who underwent kidney transplantation in our center. Hemoglobin levels were assessed at 6 and 12 months after transplantation, and anemia was defined according to World Health Organization criteria. The kidney allograft time-zero biopsy has been done in all investigated cases. The evaluated histopathological parameters of the kidney allografts included glomerulosclerosis, arteriolar hyalinosis (AH), vascular fibrous intimal thickening (CV), interstitial fibrosis, tubular atrophy, and interstitial fibrosis and tubular atrophy. The Banff Classification of Allograft Pathology criteria were followed to assess the allograft histopathological changes. Results: The prevalence of anemia was 31.3% at 6 months after transplantation and 23.5% at 12 months. There was an association between 20-50% glomerulosclerosis and PTA in both time points, independently from estimated glomerular filtration rate. AH and interstitial fibrosis were identified as independent risk factors for anemia 6 months after transplantation. Conclusion: Histopathological features of time-zero kidney biopsy may be predictors of PTA. Among them, our study recognized 20–50% degree of glomerulosclerosis, AH, and CV as the most significant risk factors for PTA.
- 1 April 2022
- Published by Edizioni Minerva Medica in Minerva Endocrinology
- Vol. 47 (1) , 11-22
Stereological properties of seminiferous tubules in infertile men with chromosomal and genetic abnormalities
Article: Stereological properties of seminiferous tubules in infertile men with chromosomal and genetic abnormalities - Minerva Endocrinology 2022 March;47(1):11-22 - Minerva Medica - Journals
- 1 April 2022
- Published by Edizioni Minerva Medica in Minerva Endocrinology
- Vol. 47 (1) , 11-22
Stereological properties of seminiferous tubules in infertile men with chromosomal and genetic abnormalities
Article: Stereological properties of seminiferous tubules in infertile men with chromosomal and genetic abnormalities - Minerva Endocrinology 2022 March;47(1):11-22 - Minerva Medica - Journals